AstraZeneca today confirmed that it delivered 5.3 million doses of its COVID-19 vaccine to the Ministry of Public Health in July, as part of an ongoing commitment to deliver 61 million doses to Thailand as soon as possible.
The July deliveries meet AstraZeneca’s projections which show that over with uninterrupted manufacturing, the company can supply between five and six million doses a month to Thailand.
As of the end of July, AstraZeneca has delivered a total of 11.3 million doses of its COVID-19 vaccine to Thailand, and the company has started delivering to nearby countries from its Thailand supply chain.
James Teague, Country President, AstraZeneca (Thailand) Ltd., said: “Our partner Siam Bioscience is performing amongst the strongest in our worldwide manufacturing network, operating at full capacity and delivering to the highest quality standards. Where possible, we will collaborate with them to deliver vaccines faster. We are proud to be working with Siam Bioscience and helping to take the people of Thailand on the path to recovery as quickly as possible by supporting the country’s mass vaccination program.”
The vaccine is around 80%-90% effective against severe disease and hospitalisation and is highly effective against all variants of concern, including Beta and Delta. Overall safety is comparable to other vaccines. Very rare thrombotic events can be treated with early diagnosis and there is no increased risk of very rare thrombotic events after the second dose.
AstraZeneca continues to supply its COVID-19 vaccine globally at no profit during the pandemic period.
The July deliveries meet AstraZeneca’s projections which show that over with uninterrupted manufacturing, the company can supply between five and six million doses a month to Thailand.
As of the end of July, AstraZeneca has delivered a total of 11.3 million doses of its COVID-19 vaccine to Thailand, and the company has started delivering to nearby countries from its Thailand supply chain.
James Teague, Country President, AstraZeneca (Thailand) Ltd., said: “Our partner Siam Bioscience is performing amongst the strongest in our worldwide manufacturing network, operating at full capacity and delivering to the highest quality standards. Where possible, we will collaborate with them to deliver vaccines faster. We are proud to be working with Siam Bioscience and helping to take the people of Thailand on the path to recovery as quickly as possible by supporting the country’s mass vaccination program.”
The vaccine is around 80%-90% effective against severe disease and hospitalisation and is highly effective against all variants of concern, including Beta and Delta. Overall safety is comparable to other vaccines. Very rare thrombotic events can be treated with early diagnosis and there is no increased risk of very rare thrombotic events after the second dose.
AstraZeneca continues to supply its COVID-19 vaccine globally at no profit during the pandemic period.
